A phase III study of dexamethasone insert, 0.4 mg (Dextenza, Ocular Therapeutix) found that the sustained-release intracanalicular insert is safe, effective, and well tolerated for treating ocular itching associated with allergic conjunctivitis.
Isunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.
Alcaftadine ophthalmic solution 0.25% was superior to olopatadine hydrochloride ophthalmic solution 0.2% in reducing the itching related to grass and tree pollens in a multicenter, randomized study in subjects with allergic conjunctivitis.
A new, first-in-class, aldehyde-trap topical drop demonstrated rapid onset of action and sustained efficacy with an acceptable safety profile in a phase II clinical trial of patients with moderate-to-severe allergic conjunctivitis.
The arrival of spring also signals the onset of ocular allergy season. Clinicians can prepare by knowing and recognizing the symptoms in their patients, as well as being informed about the latest therapies for this diagnosis.